Feed BNTX
BN

BioNTech BNTX · NASDAQ

$89.13 +1.30% (+$1.14)

Market cap
19.8B €
Enterprise value
10.4B €
P/E
-
Forward P/E
-
PEG
-
P/S
7.5x
P/FCF
38.2x
EV/EBITDA
-
ROIC
-10.6%
Gross margin
70.8%
Net margin
-64.0%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.25
Free float
99.8%

About the company

BioNTech SE is a German biotechnology company focused on the research and development of innovative drugs and therapeutic approaches. The company is well-known for its groundbreaking research and development of mRNA (messenger RNA) technology, which serves as the basis for drug and vaccine development. BioNTech collaborates with pharmaceutical and research partners worldwide and focuses on addressing serious diseases such as cancer, infectious diseases, and others. It gained significant recognition through its collaboration with Pfizer on the development and distribution of the COVID-19 vaccine, which became the first mRNA vaccine approved for emergency use. BioNTech SE adheres to high standards of scientific research and innovation and emphasizes the potential to change the way diseases are treated and prevented. Investing in BioNTech SE (BNTX) shares may be an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in an innovative company with promising medical technologies.

Sector

Healthcare

Industry

Biotechnology

CEO

Ugur Sahin

Employees

7,807

Headquarters

Mainz

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What to watch: Revenue fell by 46% a year over the last 3 years.
  • What to watch: Analysts expect revenue to fall by 35% this fiscal year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 EUR of revenue, 20 EUR is left as free cash.
  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: 9.74B € against 316.0M €.
  • What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy